Arcellx company information, Employees & Contact Information

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights Yahoo Finance

Cell Therapy Pioneer Arcellx to Showcase Innovation at Morgan Stanley Healthcare Conference 2025 Stock Titan

Aileen Fernandes The Business Journals

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights Yahoo Finance

ASH 2024 preview – Arcellx disappoints | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results PR Newswire

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma Business Wire

Heba Nowyhed The Business Journals

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program PR Newswire

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study Yahoo Finance

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors Business Wire

Heba Nowyhed | People on The Move - San Francisco Business Times The Business Journals

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH PR Newswire

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights Business Wire

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition Business Wire

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights Business Wire

Arcellx to Participate in Two Upcoming Investor Conferences Business Wire

Arcellx Provides First Quarter 2024 Financial Results Business Wire

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP PR Newswire

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights PR Newswire

Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress PR Newswire

EHA 2025 – Arcellx still hopes safety will trump efficacy | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Arcellx Reports Third Quarter 2022 Financial Results and Business Progress PR Newswire

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month GlobeNewswire

Arcellx Announces Upsizing and Pricing of Follow-On Public Offering PR Newswire

FDA Lifts Partial Clinical Hold on Arcellx’s Trial for Multiple Myeloma CAR-T CART-ddBCMA CGTLive®

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma Business Wire

Arcellx Announces Closing of Upsized Public Offering of Common Stock and Underwriters' Full Exercise of Option to Purchase Additional Shares PR Newswire

We Think Arcellx (NASDAQ:ACLX) Can Afford To Drive Business Growth Yahoo Finance

Arcellx Announces Dosing of First Patient in its Phase 1 Clinical Trial Evaluating ACLX-001, the First Therapeutic in the Dosable and Controllable ARC-SparX Platform, for the treatment of Patients with Relapsed or Refractory Multiple Myeloma PR Newswire

How Arcellx won the battle of BCMA CAR-T therapies against Legend Biotech statnews.com

Kite Inks Up-to-$4B Deal to Co-Develop Arcellx Myeloma CAR T-Cell Therapy Genetic Engineering and Biotechnology News

Safety Stands Out in Arcellx Cell Therapy’s ASH Data, But Don’t Overlook Manufacturing Advantages MedCity News

Early data from Arcellx, Gilead suggest CAR-T for multiple myeloma could offer safety benefit statnews.com

FDA Lifts Clinical Hold on BCMA-Directed Modified CAR T-Cell Therapy in Multiple Myeloma OncLive

FDA Allows iMMagine-1 Study to Continue for Patients With RRMM Targeted Oncology

Anitocabtagene autoleucel exhibits durable efficacy in high-risk advanced multiple myeloma Healio

FDA Pauses iMMagine-1 Study of CART-ddBCMA in Relapsed/Refractory Multiple Myeloma Targeted Oncology

Arcellx; Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market (ACLX) Seeking Alpha

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. Investor's Business Daily

Arcellx Impressive Safety Data Leaves Doubts (NASDAQ:ACLX) Seeking Alpha

Gilead hands Arcellx $285M to expand BCMA cell therapy deal, sparking fresh push for congested market Fierce Biotech

Kite and Arcellx expand cell therapy partnership in deal worth over $285m PMLiVE

ASCO: ‘Any way you slice’ it, Arcellx's CAR-T is matching J&J-Legend’s Carvykti, analyst says Fierce Biotech

Arcellx raises $124M in Wall Street debut to bankroll study of multiple myeloma CAR-T Fierce Biotech

Arcellx raises $85M to take anti-BCMA cell therapy into humans Fierce Biotech